Testosterone Formulations: How to Select the Right Agent Within the Class

Why Formulation Choice Matters More Than the Molecule

Every FDA-approved testosterone product delivers the same active hormone. The clinical decision is not which testosterone to prescribe but how to deliver it. Route of administration determines peak-to-trough variability, adverse-effect profile, adherence patterns, and out-of-pocket cost. The 2018 Endocrine Society Clinical Practice Guideline states that "the choice of testosterone formulation is a shared decision between the clinician and the patient, based on the patient's preference, pharmacokinetics, treatment burden, and cost" 1.

Pharmacokinetic Divergence Across Routes

Intramuscular testosterone cypionate or enanthate injected every 1 to 2 weeks produces supraphysiologic peaks within 24 to 48 hours, followed by a trough that may dip below the eugonadal range before the next dose. Transdermal gels (AndroGel, Testim, Vogelxo) maintain steadier 24-hour serum concentrations but require daily application and carry a secondary transfer warning. Oral testosterone undecanoate (Jatenzo) relies on lymphatic absorption, bypassing first-pass hepatic metabolism, and reaches steady state within 7 days of twice-daily dosing 2. Nasal testosterone (Natesto) peaks at 40 minutes post-dose and requires three-times-daily administration, producing the most physiologic circadian-like pattern among available formulations.

Clinical Impact of Peak-Trough Swings

Wide serum fluctuations from IM injections correlate with mood variability, energy dips before the next dose, and a higher incidence of erythrocytosis. A retrospective cohort analysis of 3,422 hypogonadal men found that IM testosterone users had a 37.3% rate of hematocrit exceeding 50% over 3 years, compared with 13.8% among transdermal users 3. For patients with baseline hematocrit above 48% or obstructive sleep apnea, starting with a transdermal or nasal formulation reduces the frequency of dose holds and therapeutic phlebotomy.

Intramuscular Formulations: Cypionate, Enanthate, and Undecanoate

Intramuscular injection remains the default for many clinicians because of cost, familiarity, and straightforward dose titration. Generic testosterone cypionate 200 mg/mL costs approximately $30 to $60 per month at standard replacement doses of 100 to 200 mg every 2 weeks 4.

Cypionate vs. Enanthate

Testosterone cypionate and testosterone enanthate are pharmacologically near-identical. Cypionate has an 8-day half-life; enanthate, roughly 4.5 days. In practice, both are dosed every 7 to 14 days for replacement. Enanthate is more commonly used in Europe, while cypionate dominates U.S. Prescribing. Neither formulation has demonstrated superiority in head-to-head trials. The AUA 2018 guideline treats them as interchangeable for clinical purposes 5.

Long-Acting IM Undecanoate (Aveed)

Testosterone undecanoate for IM injection (Aveed) extends the dosing interval to every 10 weeks after a loading period. This reduces injection burden but requires in-office administration with a 30-minute post-injection observation period due to the risk of pulmonary oil microembolism (POME). The FDA's REMS program mandates that Aveed can only be administered by a certified healthcare provider, which limits its use to clinic-based settings 6. In the phase 3 trial (N=130), POME events occurred in 1.5% of injections, and none were fatal.

Transdermal Options: Gels, Patches, and Solutions

Transdermal testosterone achieves the steadiest serum concentrations among non-implantable formulations. Daily application mimics the diurnal testosterone rhythm when applied in the morning.

Gel Formulations

AndroGel 1% and 1.62%, Testim 1%, and Vogelxo 1% are applied to the shoulders, upper arms, or abdomen. Absorption varies by site and skin condition. The TRAVERSE trial (N=5,246), the largest randomized cardiovascular outcomes study for TRT, used testosterone 1.62% gel and found no increase in major adverse cardiovascular events (MACE) versus placebo (hazard ratio 0.96; 95% CI 0.78 to 1.17) over a mean follow-up of 33 months 7. This trial shifted the risk-benefit conversation for transdermal testosterone in men with pre-existing CV risk factors.

The primary safety concern for gels is secondary exposure. The FDA requires a boxed warning after reports of virilization in children who contacted treated skin. Patients must wash hands immediately after application, cover the site with clothing, and shower before skin-to-skin contact with women or children.

Patches and Topical Solutions

The testosterone patch (Androderm) delivers 2 to 6 mg/day and avoids the transfer risk of gels, but adhesion problems and application-site reactions (up to 37% of users in key trials) limit adherence 8. Axiron, a topical solution applied to the axilla, provided an alternative delivery site but was discontinued in 2017. Androderm remains available but accounts for a small share of TRT prescriptions.

Oral Testosterone: Jatenzo (Testosterone Undecanoate Capsules)

Jatenzo received FDA approval in March 2019 as the first oral testosterone product for U.S. Hypogonadal men. It bypasses hepatic first-pass metabolism through lymphatic absorption, avoiding the hepatotoxicity associated with older 17-alpha-alkylated oral androgens like methyltestosterone 9.

Dosing and Monitoring

Starting dose is 237 mg twice daily with food containing at least 20 g of fat per meal. Dose titration at 4-week intervals targets a total testosterone of 300 to 1,050 ng/dL, measured 6 hours post-dose. A dose-finding study (N=166) achieved eugonadal levels in 87% of participants at the 237 mg BID dose 2.

Blood Pressure Considerations

Jatenzo's label carries a warning for dose-related increases in systolic blood pressure (mean increase of 3 to 5 mmHg in clinical trials). The Endocrine Society recommends baseline and 3-month BP monitoring when prescribing oral testosterone undecanoate. This formulation is not ideal for patients with uncontrolled hypertension (systolic ≥140 mmHg).

Nasal Testosterone: Natesto

Natesto (testosterone nasal gel, 5.5 mg per actuation) is applied as one actuation per nostril three times daily, approximately 6 to 8 hours apart. Peak serum testosterone occurs around 40 minutes post-dose and returns to near-baseline within 2 to 4 hours, producing the shortest duration of action among TRT formulations 10.

Fertility Preservation Advantage

A prospective study (N=44) of hypogonadal men using Natesto for 6 months showed that 90.9% maintained sperm concentrations above 10 million/mL, with no patient dropping below 5 million/mL 11. This contrasts sharply with IM and transdermal formulations, where spermatogenesis suppression is expected within 3 to 6 months. Dr. Ranjith Ramasamy of the University of Miami stated that "Natesto may fill a niche for hypogonadal men who desire future fertility while receiving testosterone replacement" 11. For men under 40 who have not completed family-building, Natesto or combination therapy with enclomiphene should be discussed before initiating standard TRT.

Practical Limitations

The three-times-daily schedule is a significant adherence barrier. Nasal irritation occurs in approximately 8 to 10% of users. Natesto is also incompatible with intranasal corticosteroid sprays, which creates a conflict for men with allergic rhinitis.

Subcutaneous Injection: Xyosted and Off-Label SC Cypionate

Xyosted (testosterone enanthate) is the only FDA-approved subcutaneous testosterone autoinjector. It delivers 50, 75, or 100 mg weekly via a prefilled pen to the abdomen 12.

Pharmacokinetic Advantages of Subcutaneous Dosing

Weekly subcutaneous dosing produces tighter peak-trough ratios than biweekly IM injection. A crossover pharmacokinetic study (N=19) demonstrated that SC testosterone cypionate 80 mg/week produced a coefficient of variation of 18% for serum testosterone, compared with 44% for IM cypionate 160 mg every 2 weeks 13. The AUA recognized subcutaneous self-injection as a reasonable alternative in its 2018 guideline update, though many payers still require prior authorization for branded Xyosted 5.

Off-Label SC Cypionate

Many clinics prescribe generic testosterone cypionate for subcutaneous injection at 50 to 80 mg weekly using insulin syringes. This approach costs a fraction of branded Xyosted while delivering comparable pharmacokinetics. The injection volume (0.25 to 0.4 mL) is well-tolerated in abdominal or deltoid subcutaneous tissue.

Testosterone Pellet Implants (Testopel)

Testopel involves subcutaneous implantation of 6 to 12 crystalline testosterone pellets (75 mg each) every 3 to 6 months. A minor in-office surgical procedure is required, with local anesthesia and a 5 mm trocar incision in the hip or gluteal area. Serum levels remain in the eugonadal range for 3 to 4 months in most patients, then taper 14.

When Pellets Make Sense

Pellets are best suited for patients who have demonstrated stable dose requirements over at least 6 months of injectable or transdermal therapy and who strongly prefer the lowest possible dosing frequency. Extrusion rates range from 5 to 12% in published series, and infection at the insertion site occurs in approximately 1 to 2% of procedures.

A Decision Framework for Formulation Selection

No single formulation is best for every patient. Selection should follow a structured evaluation of five domains.

Domain 1: Needle Tolerance and Administration Setting

Patients comfortable with self-injection and seeking low cost should start with generic IM or SC testosterone cypionate. Those who refuse needles are candidates for transdermal gel, oral Jatenzo, or nasal Natesto. Patients who prefer clinic-only visits every 10 weeks may benefit from Aveed, provided the REMS observation is acceptable.

Domain 2: Hematologic Risk

Baseline hematocrit above 48%, history of polycythemia vera, or concurrent use of erythropoiesis-stimulating agents warrants a formulation with lower erythrocytosis risk. Transdermal gel, nasal testosterone, and oral Jatenzo produce fewer hematocrit elevations than IM injections 3.

Domain 3: Fertility Status

Men who may want biological children within 6 to 12 months should generally avoid TRT altogether. If testosterone replacement is strongly indicated, Natesto offers the best evidence for spermatogenesis preservation 11. An alternative strategy is combining low-dose IM or SC testosterone with enclomiphene or hCG 1,500 IU SC twice weekly to maintain intratesticular testosterone.

Domain 4: Cardiovascular and Blood Pressure Profile

The TRAVERSE trial supports the cardiovascular safety of transdermal testosterone gel in men aged 45 to 80 7. For patients with uncontrolled hypertension, Jatenzo's dose-related BP effect makes it a less attractive choice. Dr. Shalender Bhasin, lead investigator of the TRAVERSE trial, noted that "these findings should reassure clinicians that testosterone treatment in middle-aged and older men with hypogonadism and cardiovascular risk does not increase short- to intermediate-term risk of MACE" 7.

Domain 5: Cost and Insurance Coverage

Generic cypionate (IM or SC) remains the most affordable option at $30 to $60/month. Transdermal gels range from $50 to $150/month with commercial insurance. Branded products like Jatenzo ($600 to $900/month), Xyosted ($400 to $600/month), and Aveed ($1,500 to $2,500 per 10-week injection) require prior authorization from most payers and may be inaccessible for patients on high-deductible plans.

Monitoring Across Formulations

Regardless of route, the Endocrine Society guideline recommends measuring total testosterone, hematocrit, and PSA at 3 to 6 months after initiation and annually thereafter 1. Timing of the testosterone draw varies by formulation: midpoint between injections for IM, any morning for transdermal gel, 6 hours post-dose for Jatenzo, and 1 to 2 hours after the second daily dose for Natesto. Lipid panels and hepatic function should be checked at baseline and 12 months. Bone mineral density testing is appropriate in men with a history of fragility fracture or glucocorticoid use. The target total testosterone range for all formulations is 450 to 600 ng/dL at the trough or steady-state measurement.